{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:42:14Z","timestamp":1793403734206,"version":"4.5.0"},"reference-count":169,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.blre.2016.10.001","type":"journal-article","created":{"date-parts":[[2016,10,16]],"date-time":"2016-10-16T21:15:24Z","timestamp":1476652524000},"page":"77-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["NF-\u03baB signaling pathway and its potential as a target for therapy in lymphoid neoplasms"],"prefix":"10.1016","volume":"31","author":[{"given":"Li","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2016.10.001_bb0005","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.blre.2016.10.001_bb0015","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2016.10.001_bb0020","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1093\/emboj\/16.20.6131","article-title":"Latent membrane protein 1 of Epstein\u2013Barr virus mimics a constitutively active receptor molecule","volume":"16","author":"Gires","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.blre.2016.10.001_bb0025","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nrmicro2015","article-title":"The curious case of the tumour virus: 50years of Burkitt's lymphoma","volume":"6","author":"Thorley-Lawson","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.blre.2016.10.001_bb0030","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1182\/blood.V99.4.1398","article-title":"BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression","volume":"99","author":"Maes","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0035","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1038\/onc.2013.195","article-title":"The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-kappaB signaling","volume":"33","author":"Rosebeck","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2016.10.001_bb0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/8767","article-title":"Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32)","volume":"22","author":"Zhang","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2016.10.001_bb0045","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1073\/pnas.1200081109","article-title":"MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20)","volume":"109","author":"Kim","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2016.10.001_bb0050","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ni.2060","article-title":"Inflammation meets cancer, with NF-kappaB as the matchmaker","volume":"12","author":"Ben-Neriah","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2016.10.001_bb0055","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.str.2005.06.018","article-title":"NF-kappaB RelB forms an intertwined homodimer","volume":"13","author":"Huang","year":"2005","journal-title":"Structure"},{"key":"10.1016\/j.blre.2016.10.001_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-065X.2012.01102.x","article-title":"It takes two to tango: IkappaBs, the multifunctional partners of NF-kappaB","volume":"246","author":"Hinz","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2016.10.001_bb0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1600-065X.2012.01107.x","article-title":"IKK biology","volume":"246","author":"Liu","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2016.10.001_bb0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-065X.2012.01098.x","article-title":"Regulation of NF-kappaB by ubiquitination and degradation of the IkappaBs","volume":"246","author":"Kanarek","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2016.10.001_bb0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1600-065X.2012.01095.x","article-title":"Regulation of cell death and autophagy by IKK and NF-kappaB: critical mechanisms in immune function and cancer","volume":"246","author":"Baldwin","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2016.10.001_bb0080","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1097-2765(02)00697-4","article-title":"Two pathways to NF-kappaB","volume":"10","author":"Pomerantz","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0085","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.it.2004.03.008","article-title":"The two NF-kappaB activation pathways and their role in innate and adaptive immunity","volume":"25","author":"Bonizzi","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.blre.2016.10.001_bb0090","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/intimm\/dxh263","article-title":"Activation of NF-kappaB promotes the transition of large, CD43+ pre-B cells to small, CD43- pre-B cells","volume":"17","author":"Jimi","year":"2005","journal-title":"Int Immunol"},{"key":"10.1016\/j.blre.2016.10.001_bb0095","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ni.1732","article-title":"Development of immunoglobulin lambda-chain-positive B cells, but not editing of immunoglobulin kappa-chain, depends on NF-kappaB signals","volume":"10","author":"Derudder","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2016.10.001_bb0100","doi-asserted-by":"crossref","first-page":"7729","DOI":"10.4049\/jimmunol.0803281","article-title":"B cell receptor-mediated sustained c-Rel activation facilitates late transitional B cell survival through control of B cell activating factor receptor and NF-kappaB2","volume":"182","author":"Castro","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2016.10.001_bb0105","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.4049\/jimmunol.170.12.5820","article-title":"Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors","volume":"170","author":"Smith","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2016.10.001_bb0110","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.4049\/jimmunol.167.10.5628","article-title":"Inefficient ZAP-70 phosphorylation and decreased thymic selection in vivo result from inhibition of NF-kappaB\/Rel","volume":"167","author":"Mora","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2016.10.001_bb0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/imr.12033","article-title":"NF-kappaB: roles and regulation in different CD4(+) T-cell subsets","volume":"252","author":"Oh","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2016.10.001_bb0120","doi-asserted-by":"crossref","first-page":"18529","DOI":"10.1073\/pnas.1204557109","article-title":"T cell receptor\/CARMA1\/NF-kappaB signaling controls T-helper (Th) 17 differentiation","volume":"109","author":"Molinero","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2016.10.001_bb0125","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1600-065X.2011.01090.x","article-title":"NF-kappaB subunit specificity in hemopoiesis","volume":"246","author":"Gerondakis","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2016.10.001_bb0130","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00018-013-1545-4","article-title":"NF-kappaB pathways in hematological malignancies","volume":"71","author":"Gasparini","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.blre.2016.10.001_bb0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.blre.2016.10.001_bb0140","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.1038\/sj.onc.1207120","article-title":"Epstein\u2013Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma\/NEMO-independent signalling pathway","volume":"22","author":"Eliopoulos","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2016.10.001_bb0145","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1038\/sj.onc.1207705","article-title":"Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation","volume":"23","author":"Broemer","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2016.10.001_bb0150","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0155","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-cell receptor signaling as a driver of lymphoma development and evolution","volume":"23","author":"Niemann","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.blre.2016.10.001_bb0160","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1084\/jem.20020408","article-title":"Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha","volume":"195","author":"Saijo","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2016.10.001_bb0165","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2008-06-160713","article-title":"PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia","volume":"113","author":"Holler","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2012.12.003","article-title":"Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo","volume":"23","author":"Lutzny","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0175","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2007-05-088591","article-title":"Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells","volume":"111","author":"Kim","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0180","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-10-2525","article-title":"Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas","volume":"71","author":"Naylor","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0185","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1182\/blood.V88.9.3502.bloodjournal8893502","article-title":"The protein product of the proto-oncogene c-cbl forms a complex with phosphatidylinositol 3-kinase p85 and CD19 in anti-IgM-stimulated human B-lymphoma cells","volume":"88","author":"Beckwith","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0190","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V99.2.584","article-title":"Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement","volume":"99","author":"Inabe","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0195","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1158\/1078-0432.CCR-11-1402","article-title":"Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia","volume":"18","author":"Herman","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0200","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0205","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.coi.2011.01.001","article-title":"Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation","volume":"23","author":"Baracho","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.blre.2016.10.001_bb0210","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature B cell survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0215","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.celrep.2013.10.022","article-title":"Context-specific BAFF-R signaling by the NF-kappaB and PI3K pathways","volume":"5","author":"Jellusova","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2016.10.001_bb0220","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.1008969108","article-title":"Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells","volume":"108","author":"Kloo","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2016.10.001_bb0225","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ccr.2013.05.002","article-title":"SYK inhibition modulates distinct PI3K\/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas","volume":"23","author":"Chen","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0230","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/0092-8674(90)90276-K","article-title":"Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal","volume":"62","author":"Ghosh","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0235","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/0092-8674(90)90275-J","article-title":"The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product","volume":"62","author":"Kieran","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0240","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1182\/blood.V87.10.4340.bloodjournal87104340","article-title":"High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin\/Reed\u2013Sternberg cells","volume":"87","author":"Bargou","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0245","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V94.9.3129","article-title":"Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed\u2013Sternberg cells","volume":"94","author":"Emmerich","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0250","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1038\/sj.onc.1202893","article-title":"Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha","volume":"18","author":"Cabannes","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2016.10.001_bb0255","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.191.2.395","article-title":"Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma","volume":"191","author":"Jungnickel","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2016.10.001_bb0260","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.blre.2016.10.001_bb0265","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.blre.2016.10.001_bb0270","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(00)03571-6","article-title":"Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy","volume":"357","author":"Liu","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2016.10.001_bb0275","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nature09121","article-title":"Helical assembly in the MyD88\u2013IRAK4\u2013IRAK2 complex in TLR\/IL-1R signalling","volume":"465","author":"Lin","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.blre.2016.10.001_bb0280","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.blre.2016.10.001_bb0285","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.blre.2016.10.001_bb0290","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20062041","article-title":"Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma","volume":"204","author":"Lenz","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2016.10.001_bb0295","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMcibr067155","article-title":"A closer look at follicular lymphoma","volume":"356","author":"Staudt","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2016.10.001_bb0300","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood.V92.8.2871","article-title":"DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma","volume":"92","author":"Vaandrager","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0305","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tibs.2012.04.002","article-title":"Nuclear factor-kappaB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect","volume":"37","author":"Johnson","year":"2012","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.blre.2016.10.001_bb0310","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1535-6108(02)00068-5","article-title":"p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy","volume":"1","author":"Tergaonkar","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0315","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1128\/MCB.19.5.3485","article-title":"Transcriptional cross talk between NF-kappaB and p53","volume":"19","author":"Webster","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.blre.2016.10.001_bb0320","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.molcel.2007.02.019","article-title":"Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB","volume":"26","author":"Huang","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0325","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1038\/sj.emboj.7601343","article-title":"Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit","volume":"25","author":"Schumm","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/j.blre.2016.10.001_bb0330","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2016.10.001_bb0335","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood-2014-01-553412","article-title":"FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-kappaB to promote survival of human B cells","volume":"124","author":"van Keimpema","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0340","doi-asserted-by":"crossref","first-page":"9079","DOI":"10.1073\/pnas.0402415101","article-title":"Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2\/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis","volume":"101","author":"Stoffel","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2016.10.001_bb0345","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1002\/ijc.29301","article-title":"Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-kappaB pathway","volume":"136","author":"Ramachandiran","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2016.10.001_bb0350","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/leu.2014.351","article-title":"MicroRNAs in B-cell lymphomas: how a complex biology gets more complex","volume":"29","author":"Musilova","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.10.001_bb0355","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/leu.2015.101","article-title":"MicroRNA-124 links p53 to the NF-kappaB pathway in B-cell lymphomas","volume":"29","author":"Jeong","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.10.001_bb0360","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1093\/emboj\/cdf389","article-title":"Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B","volume":"21","author":"Mathas","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.blre.2016.10.001_bb0365","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00109-013-1081-6","article-title":"RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow","volume":"92","author":"Xu","year":"2014","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.blre.2016.10.001_bb0370","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/sj.leu.2404723","article-title":"Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB\/p52) in non-Hodgkin's lymphoma cells","volume":"21","author":"Lwin","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.10.001_bb0375","doi-asserted-by":"crossref","first-page":"16471","DOI":"10.18632\/oncotarget.4106","article-title":"Neutrophils trigger a NF-kappaB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas","volume":"6","author":"Gregoire","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2016.10.001_bb0380","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4110\/in.2014.14.6.296","article-title":"Simultaneous inhibition of CXCR4 and VLA-4 exhibits combinatorial effect in overcoming stroma-mediated chemotherapy resistance in mantle cell lymphoma cells","volume":"14","author":"Kim","year":"2014","journal-title":"Immune Netw"},{"key":"10.1016\/j.blre.2016.10.001_bb0385","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/leu.2011.12","article-title":"IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells","volume":"25","author":"Coscia","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.10.001_bb0390","doi-asserted-by":"crossref","first-page":"11421","DOI":"10.1073\/pnas.97.21.11421","article-title":"RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function","volume":"97","author":"O'Sullivan","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2016.10.001_bb0395","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1158\/1078-0432.CCR-09-0213","article-title":"Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity","volume":"15","author":"Boll","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0400","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0405","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1073\/pnas.0702409104","article-title":"miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely","volume":"104","author":"Zhou","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2016.10.001_bb0410","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ijc.22800","article-title":"MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma","volume":"121","author":"Lawrie","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2016.10.001_bb0415","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood-2009-09-243147","article-title":"microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma","volume":"115","author":"Zhao","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0420","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1073\/pnas.0500613102","article-title":"Accumulation of miR-155 and BIC RNA in human B cell lymphomas","volume":"102","author":"Eis","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2016.10.001_bb0425","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2141.2008.07237.x","article-title":"MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas","volume":"142","author":"Roehle","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.10.001_bb0430","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1182\/blood-2010-05-285064","article-title":"MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia","volume":"117","author":"Vargova","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0435","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/blood-2008-10-184077","article-title":"Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas","volume":"113","author":"Malumbres","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0440","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1073\/pnas.0602266103","article-title":"Pre-B cell proliferation and lymphoblastic leukemia\/high-grade lymphoma in E(mu)-miR155 transgenic mice","volume":"103","author":"Costinean","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2016.10.001_bb0445","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2009-05-220814","article-title":"Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice","volume":"114","author":"Costinean","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0450","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1074\/jbc.M110.177063","article-title":"NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155\/PU.1 pathway","volume":"286","author":"Thompson","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2016.10.001_bb0455","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2199-14-24","article-title":"Identification of an NF-kappaB p50\/p65-responsive site in the human MIR155HG promoter","volume":"14","author":"Thompson","year":"2013","journal-title":"BMC Mol Biol"},{"key":"10.1016\/j.blre.2016.10.001_bb0460","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1093\/nar\/gkn666","article-title":"Epstein\u2013Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway","volume":"36","author":"Gatto","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0465","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4161\/rna.4.3.5206","article-title":"Epstein\u2013Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a","volume":"4","author":"Motsch","year":"2007","journal-title":"RNA Biol"},{"key":"10.1016\/j.blre.2016.10.001_bb0470","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1128\/JVI.07056-11","article-title":"The Epstein\u2013Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells","volume":"86","author":"Forte","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.blre.2016.10.001_bb0475","doi-asserted-by":"crossref","first-page":"11023","DOI":"10.18632\/oncotarget.3433","article-title":"MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1","volume":"6","author":"Contreras","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2016.10.001_bb0480","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1182\/blood-2011-02-339556","article-title":"Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets","volume":"119","author":"Arribas","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0485","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.blre.2016.10.001_bb0490","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1084\/jem.20142009","article-title":"Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia","volume":"212","author":"Mansouri","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2016.10.001_bb0495","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1084\/jem.2126insight4","article-title":"Augmenting NF-kappaB in poor-risk CLL: a general paradigm for other cancers?","volume":"212","author":"Tuveson","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2016.10.001_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004642","article-title":"Regulation of p53 and Rb links the alternative NF-kappaB pathway to EZH2 expression and cell senescence","volume":"10","author":"Iannetti","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.blre.2016.10.001_bb0505","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2013-02-486035","article-title":"A sleeping beauty screen reveals NF-kB activation in CLL mouse model","volume":"121","author":"Zanesi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0510","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0092-8674(00)80957-5","article-title":"Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types","volume":"96","author":"Willis","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0515","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1038\/sj.onc.1203018","article-title":"A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"18","author":"Akagi","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2016.10.001_bb0520","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-11-0467","article-title":"MALT1 protease: a new therapeutic target in B lymphoma and beyond?","volume":"17","author":"McAllister-Lucas","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0525","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1198946","article-title":"Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation","volume":"331","author":"Rosebeck","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.blre.2016.10.001_bb0530","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nri2656","article-title":"The follicular versus marginal zone B lymphocyte cell fate decision","volume":"9","author":"Pillai","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2016.10.001_bb0535","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/leu.2014.330","article-title":"KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype","volume":"29","author":"Clipson","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.10.001_bb0540","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2016.08.002","article-title":"NF-kappaB deregulation in splenic marginal zone lymphoma","author":"Spina","year":"2016","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.blre.2016.10.001_bb0550","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3324\/haematol.2011.054080","article-title":"BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas","volume":"97","author":"Yan","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2016.10.001_bb0555","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2011-06-359166","article-title":"Alteration of BIRC3 and multiple other NF-kappa B pathway genes in splenic marginal zone lymphoma","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0560","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2016.10.001_bb0565","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2016.10.001_bb0570","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2013-06-508028","article-title":"IkappaB-zeta controls the constitutive NF-kappaB target gene network and survival of ABC DLBCL","volume":"122","author":"Nogai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0575","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1101\/gad.1553707","article-title":"Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB","volume":"21","author":"Yang","year":"2007","journal-title":"Genes Dev"},{"key":"10.1016\/j.blre.2016.10.001_bb0580","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma","volume":"111","author":"Lam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0585","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/ni1357","article-title":"Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination","volume":"7","author":"Klein","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2016.10.001_bb0590","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ccr.2010.10.030","article-title":"BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma","volume":"18","author":"Mandelbaum","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0595","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1182\/blood-2005-09-3778","article-title":"Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas","volume":"107","author":"Tam","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0600","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1182\/blood-2008-01-136440","article-title":"Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression","volume":"112","author":"Schmidlin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0605","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ccr.2010.11.024","article-title":"Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma","volume":"18","author":"Calado","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2016.10.001_bb0610","doi-asserted-by":"crossref","first-page":"23157","DOI":"10.18632\/oncotarget.4319","article-title":"Prognostic impact of c-rel nuclear expression and REL amplification and crosstalk between c-rel and the p53 pathway in diffuse large B-cell lymphoma","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2016.10.001_bb0615","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/modpathol.2015.76","article-title":"Evaluation of NF-kappa B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions","volume":"28","author":"Ok","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2016.10.001_bb0620","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/modpathol.2014.34","article-title":"NFkappaB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma","volume":"27","author":"Odqvist","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2016.10.001_bb0625","doi-asserted-by":"crossref","first-page":"071801","DOI":"10.1103\/PhysRevLett.109.071801","article-title":"Search for pair production of a new b\u2032 quark that decays into a Z boson and a bottom quark with the ATLAS detector","volume":"109","author":"Aad","year":"2012","journal-title":"Phys Rev Lett"},{"key":"10.1016\/j.blre.2016.10.001_bb0630","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12308-009-0021-4","article-title":"Prognostic impact of C-REL expression in diffuse large B-cell lymphoma","volume":"2","author":"Curry","year":"2009","journal-title":"J Hematop"},{"key":"10.1016\/j.blre.2016.10.001_bb0635","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/scbi.2001.0410","article-title":"LMP1 structure and signal transduction","volume":"11","author":"Eliopoulos","year":"2001","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.blre.2016.10.001_bb0640","doi-asserted-by":"crossref","first-page":"12592","DOI":"10.1073\/pnas.94.23.12592","article-title":"The Epstein\u2013Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB","volume":"94","author":"Izumi","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2016.10.001_bb0645","doi-asserted-by":"crossref","first-page":"9680","DOI":"10.1128\/JVI.01001-07","article-title":"Unique signaling properties of CTAR1 in LMP1-mediated transformation","volume":"81","author":"Mainou","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.blre.2016.10.001_bb0650","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2016.10.001_bb0655","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1158\/0008-5472.CAN-15-0748","article-title":"PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-kappaB","volume":"76","author":"Karyampudi","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0660","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1038\/emboj.2012.63","article-title":"EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency","volume":"31","author":"Riley","year":"2012","journal-title":"EMBO J"},{"key":"10.1016\/j.blre.2016.10.001_bb0665","doi-asserted-by":"crossref","first-page":"11025","DOI":"10.1093\/nar\/gku826","article-title":"NF-kappaB directly mediates epigenetic deregulation of common microRNAs in Epstein\u2013Barr virus-mediated transformation of B-cells and in lymphomas","volume":"42","author":"Vento-Tormo","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002193","article-title":"A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia","volume":"7","author":"Qiu","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.blre.2016.10.001_bb0675","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood-2004-09-3748","article-title":"Azidothymidine inhibits NF-kappaB and induces Epstein\u2013Barr virus gene expression in Burkitt lymphoma","volume":"106","author":"Kurokawa","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0680","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3892\/ijo.2013.1871","article-title":"Epstein\u2013Barr virus latent membrane protein 1 induces CD69 expression through activation of nuclear factor-kappaB","volume":"42","author":"Ishikawa","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.blre.2016.10.001_bb0685","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1128\/JVI.02264-08","article-title":"c-Myc and Rel\/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein\u2013Barr virus-immortalized B cells","volume":"83","author":"Faumont","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.blre.2016.10.001_bb0690","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/modpathol.2012.52","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation","volume":"25","author":"Montes-Moreno","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2016.10.001_bb0695","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-13-3157","article-title":"Prevalence and clinical implications of epstein\u2013barr virus infection in de novo diffuse large B-cell lymphoma in western countries","volume":"20","author":"Ok","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0700","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3109\/10428194.2014.944522","article-title":"Prevalence of targetable oncogenic mutations and genomic alterations in Epstein\u2013Barr virus-associated diffuse large B-cell lymphoma of the elderly","volume":"56","author":"Gebauer","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2016.10.001_bb0705","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.1073\/pnas.0902636106","article-title":"Inositol phosphatase SHIP1 is a primary target of miR-155","volume":"106","author":"O'Connell","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2016.10.001_bb0710","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1084\/jem.20072581","article-title":"An Epstein\u2013Barr virus-encoded microRNA targets PUMA to promote host cell survival","volume":"205","author":"Choy","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2016.10.001_bb0715","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/leu.2011.189","article-title":"Epstein\u2013Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma","volume":"26","author":"Martin-Perez","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.10.001_bb0720","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/path.2279","article-title":"BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas","volume":"214","author":"Perez-Rosado","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.blre.2016.10.001_bb0725","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1182\/blood-2006-05-020545","article-title":"Bmi-1 is induced by the Epstein\u2013Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells","volume":"109","author":"Dutton","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0730","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1038\/sj.onc.1208564","article-title":"Aberrant NF-kappaB2\/p52 expression in Hodgkin\/Reed\u2013Sternberg cells and CD30-transformed rat fibroblasts","volume":"24","author":"Nonaka","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2016.10.001_bb0735","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1038\/sj.onc.1203177","article-title":"Latent membrane protein 1 associated signaling pathways are important in tumor cells of Epstein\u2013Barr virus negative Hodgkin's disease","volume":"18","author":"Knecht","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2016.10.001_bb0740","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/leu.2011.265","article-title":"Notch is an essential upstream regulator of NF-kappaB and is relevant for survival of Hodgkin and Reed\u2013Sternberg cells","volume":"26","author":"Schwarzer","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2016.10.001_bb0745","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2004-09-3620","article-title":"Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas","volume":"106","author":"Mathas","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0750","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","article-title":"Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia","volume":"17","author":"Amrein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0755","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2013.10.004","article-title":"Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study","volume":"38","author":"Kater","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0760","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdm463","article-title":"A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"19","author":"Morschhauser","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2016.10.001_bb0765","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/bjh.12853","article-title":"Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma","volume":"166","author":"Schwartzberg","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.10.001_bb0770","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0775","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2016.10.001_bb0780","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjh.12915","article-title":"Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study","volume":"166","author":"Evens","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2016.10.001_bb0785","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","article-title":"MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma","volume":"116","author":"Milhollen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0790","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1182\/blood-2015-04-640920","article-title":"Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo","volume":"127","author":"Czuczman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0795","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-15-1237","article-title":"Phase I study of the novel investigational NEDD8-activating enzyme inhibitor Pevonedistat (MLN4924) in patients with relapsed\/refractory multiple myeloma or lymphoma","volume":"22","author":"Shah","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0800","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1158\/1078-0432.CCR-11-0821","article-title":"A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas","volume":"17","author":"Rajan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2016.10.001_bb0805","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/bjc.2015.422","article-title":"Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies","volume":"114","author":"Yong","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2016.10.001_bb0810","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2010-04-278853","article-title":"The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP\/Grp78","volume":"117","author":"Roue","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0815","doi-asserted-by":"crossref","first-page":"40981","DOI":"10.18632\/oncotarget.5715","article-title":"The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia","volume":"6","author":"Kaufman","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2016.10.001_bb0820","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2016.10.001_bb0825","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2015.10.005","article-title":"A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","volume":"54","author":"Flinn","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2016.10.001_bb0830","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2016.10.001_bb0835","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2016.10.001_bb0840","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2016.10.001_bb0845","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16300467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16300467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T13:38:25Z","timestamp":1657460305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X16300467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":169,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0268960X16300467"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2016.10.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NF-\u03baB signaling pathway and its potential as a target for therapy in lymphoid neoplasms","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2016.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}